Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines

2020 Dyslipidemia CPG

Authors

  • Lourdes Ella Gonzalez-Santos University of the Philippines College of Medicine-Philippine General Hospital
  • Raymond Oliva University of the Philippines College of Medicine-Philippine General Hospital https://orcid.org/0000-0001-8432-486X
  • Cecilia Jimeno University of the Philippines College of Medicine https://orcid.org/0000-0002-7658-0123
  • Eddieson Gonzales Batangas Medical Center https://orcid.org/0000-0001-5435-091X
  • Maria Margarita Balabagno Perpetual Help DALTA Medical Center, Las Pinas
  • Deborah Ona University of the Philippines College of Medicine-Philippine General Hospital
  • Jude Erric Cinco The Medical City, Pasig City
  • Agnes Baston Emilio Aguinaldo College Medical Center-Cavite
  • Imelda Caole-Ang Pamantasan ng Lungsod ng Maynila https://orcid.org/0000-0003-3080-8548
  • Mia Fojas University of the Philippines College of Medicine
  • Ruzenette Felicitas Hernandez De La Salle University Medical Center and De La Salle Health Science Institute, College of Medicine, Dasmarinas, Cavite
  • Ma. Cristina Macrohon-Valdez St. Luke's Medical Center, Global City, Taguig
  • Ma. Theresa Rosqueta Philippine Heart Center
  • Felix Eduardo Punzalan University of the Philippines College of Medicine-Philippine General Hospital
  • Elmer Jasper Llanes University of the Philippines College of Medicine-Philippine General Hospital https://orcid.org/0000-0003-3127-7056

DOI:

https://doi.org/10.15605/jafes.036.01.01

Keywords:

guidelines, dyslipidemia, cardiovascular prevention, familial hypercholesterolemia, diabetes mellitus

Abstract

Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The need to treat and manage elevated cholesterol levels, both pharmacologic and non-pharmacologic, is of utmost importance. Different medical societies and groups bonded together to formulate the 2020 Philippine Clinical Practice Guidelines for dyslipidemia. The group raised nine clinical questions that are important in dyslipidemia management. A technical working group analyzed the clinical questions dealing with non-pharmacologic management, primary prevention for both non-diabetic and individuals with diabetes, familial hypercholesterolemia, secondary prevention, adverse events of statins and the use of other lipid parameters as measurement of risk for cardiovascular disease. Randomized controlled trials and meta-analyses were included in the GRADE-PRO analysis to come up with the statements answering the clinical questions. The statements were presented to a panel consisting of government agencies, members of the different medical societies, and private institutions, and the statements were voted upon to come up with the final statements of the 2020 practice guidelines. The 2020 CPG is aimed for the Filipino physician to confidently care for the individual with dyslipidemia and eventually, lower his risk for cardiovascular disease.

Downloads

Download data is not yet available.

Author Biographies

Lourdes Ella Gonzalez-Santos, University of the Philippines College of Medicine-Philippine General Hospital

Division of Hypertension, Department of Medicine

Raymond Oliva, University of the Philippines College of Medicine-Philippine General Hospital

Division of Hypertension, Department of Medicine

Cecilia Jimeno, University of the Philippines College of Medicine

Department of Pharmacology and Toxicology

Eddieson Gonzales, Batangas Medical Center

Department of Internal Medicine

Maria Margarita Balabagno, Perpetual Help DALTA Medical Center, Las Pinas

Department of Cardiology

Deborah Ona, University of the Philippines College of Medicine-Philippine General Hospital

Division of Hypertension, Department of Medicine

Jude Erric Cinco, The Medical City, Pasig City

Department of Cardiology

Agnes Baston, Emilio Aguinaldo College Medical Center-Cavite

Department of Internal Medicine

Imelda Caole-Ang, Pamantasan ng Lungsod ng Maynila

College of Medicine

Mia Fojas, University of the Philippines College of Medicine

Department of Biochemistry and Molecular Biology

Ruzenette Felicitas Hernandez, De La Salle University Medical Center and De La Salle Health Science Institute, College of Medicine, Dasmarinas, Cavite

Department of Pediatrics

Ma. Cristina Macrohon-Valdez, St. Luke's Medical Center, Global City, Taguig

Institute of Neurosciences

Felix Eduardo Punzalan, University of the Philippines College of Medicine-Philippine General Hospital

Division of Cardiovascular Medicine, Department of Medicine

Elmer Jasper Llanes, University of the Philippines College of Medicine-Philippine General Hospital

Division of Cardiovascular Medicine, Department of Medicine

References

Philippine Lipid and Atherosclerosis Society / Philippine Heart Association / Philippine Society of Endocrinology, Diabetes and Metabolism. 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines. https://www.philheart.org/index.php/guidelines/142-dyslipidemia-guidelines. Accessed February 1, 2020.

GRADE your evidence and improve your guideline in development in health care. https://gradepro.org.

Breda Eubank, Mohtadi NG, Lafve MR, et al. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med Res Methodol. 2016;16:56. https://www.ncbi.nlm.nih.gov/pubmed/27206853. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875724. https://doi.org/10.1186/s12874-016-0165-8.

Pijlman A, Huijgen R, Verhagen SN, et al. (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209(1):189–94. https://www.ncbi.nlm.nih.gov/pubmed/19818960. https://doi.org/10.1016/j.atherosclerosis.2009.09.014.

Expert Panel on Integrated Guidelines for cardiovascular health and risk reduction in children and adolescents, National Heart, Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011;128 (Suppl 5):S213-56. https://www.ncbi.nlm.nih.gov/pubmed/22084329. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536582. https://doi.org/10.1542/peds.2009-2107C.

Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children. J Clin Endocrinol Metab. 2014;99(9):3093-102. https://www.ncbi.nlm.nih.gov/pubmed/24848708. https://doi.org/10.1210/jc.2013-3860.

Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet. 2010; 376(9753):1658-69. https://www.ncbi.nlm.nih.gov/pubmed/21067805. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988223. https://doi.org/10.1016/S0140-6736(10)60310-8.

de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004;292(11):1307-16. https://www.ncbi.nlm.nih.gov/pubmed/15337732. https://doi.org/10.1001/jama.292.11.1307.

LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. https://www.ncbi.nlm.nih.gov/pubmed/15755765. https://doi.org/10.1056/NEJMoa050461.

Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA.2005;294(19):2437-45. https://www.ncbi.nlm.nih.gov/pubmed/16287954. https://doi.org/10.1001/jama.294.19.2437.

Published

2021-03-10

How to Cite

Gonzalez-Santos, L. E., Oliva, R., Jimeno, C., Gonzales, E., Balabagno, M. M., Ona, D., … Llanes, E. J. (2021). Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines: 2020 Dyslipidemia CPG. Journal of the ASEAN Federation of Endocrine Societies, 36(1), 5–11. https://doi.org/10.15605/jafes.036.01.01

Issue

Section

Original Articles